Cargando…

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis

BACKGROUND: In March 2020, the Ontario government declared a state of emergency due to the growing risk of COVID-19. In response, new guidance for the management of opioid agonist therapy (OAT) was released, which included the expansion of eligibility for take-home doses. We investigated the impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitchen, Sophie A., Campbell, Tonya J., Men, Siyu, Bozinoff, Nikki, Tadrous, Mina, Antoniou, Tony, Wyman, Jennifer, Werb, Dan, Munro, Charlotte, Gomes, Tara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885322/ https://www.ncbi.nlm.nih.gov/pubmed/35272107 http://dx.doi.org/10.1016/j.drugpo.2022.103644

Ejemplares similares

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis
por: Garg, Ria, et al.
Publicado: (2022)

Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2022)

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population‐based propensity‐score matched cohort study
por: Gomes, Tara, et al.
Publicado: (2022)

Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population‐based time–series analysis
por: Antoniou, Tony, et al.
Publicado: (2021)

Changing patterns of opioid initiation for pain management in Ontario, Canada: A population-based cross-sectional study
por: Gomes, Tara, et al.
Publicado: (2022)

The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study
por: Campbell, Tonya J., et al.
Publicado: (2023)

Trends in Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2022)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

Measuring the Burden of Opioid-related Mortality in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2019)

The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study
por: Choremis, Beatrice, et al.
Publicado: (2019)

Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic
por: Gomes, Tara, et al.
Publicado: (2021)

New opioid use and risk of opioid-related adverse events among adults with intellectual and developmental disabilities in Ontario, Canada
por: Guan, Qi, et al.
Publicado: (2022)

Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada
por: Fenna, Jennifer, et al.
Publicado: (2021)

Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study
por: Pasricha, Sachin V., et al.
Publicado: (2018)

Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study
por: Antoniou, Tony, et al.
Publicado: (2023)

Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis
por: Gomes, Tara, et al.
Publicado: (2021)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Comparison of claims from high–drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis
por: Tadrous, Mina, et al.
Publicado: (2021)

Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study
por: Martins, Diana, et al.
Publicado: (2020)

Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
por: Bouck, Zachary, et al.
Publicado: (2022)

Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario
por: Gomes, Tara, et al.
Publicado: (2022)

Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019
por: Camden, Andi, et al.
Publicado: (2021)

Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
por: Kouyoumdjian, Fiona G., et al.
Publicado: (2018)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study
por: Gomes, Tara, et al.
Publicado: (2021)

Behind the Counter: Exploring Pharmacists’ Stressors and Lessons Learned During the Pandemic in Ontario, Canada
por: Zahoor, Zoha, et al.
Publicado: (2023)

The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis
por: Boone, Charlotte G., et al.
Publicado: (2021)

Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis
por: Chang, Ann, et al.
Publicado: (2022)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study
por: Bardwell, Geoff, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the provision of routine childhood immunizations in Ontario, Canada
por: Piché-Renaud, Pierre-Philippe, et al.
Publicado: (2021)

Using Administrative Data to Explore Potentially Aberrant Provision of Virtual Care During COVID-19: Retrospective Cohort Study of Ontario Provincial Data
por: Stamenova, Vess, et al.
Publicado: (2021)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis
por: Bodkin, Claire, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e2791fhq7medeuctumddbnu579